CHIESI FARMACEUTICI SPA

Their core work

Chiesi Farmaceutici is a major Italian pharmaceutical company headquartered in Parma, focused on developing therapies for respiratory diseases, neonatal care, and rare diseases. In H2020, they contributed pharmaceutical expertise to clinical trials targeting neurodegenerative conditions and neonatal brain injury, while also investing in advanced drug discovery methods. Their participation reflects an industry partner bringing drug development capabilities and clinical trial infrastructure to academic-led research consortia.

What they specialise in

How they've shifted over time

Chiesi's early H2020 involvement (2015) centered on Parkinson's disease therapeutics, specifically iron chelation and oxidative stress as disease-modifying mechanisms. By 2019-2020, their focus shifted toward neonatal neuroprotection and stem cell therapy for preterm birth complications, alongside investment in drug discovery infrastructure (MS4Drug). This evolution suggests a broadening from single-disease clinical trials toward platform capabilities in both neonatal care and analytical drug discovery methods.

Chiesi is deepening its commitment to neonatal medicine while building in-house drug discovery capabilities, making them a strong partner for perinatal research and translational pharma projects.

How they like to work

Chiesi primarily joins consortia as an industry participant (2 of 3 projects), bringing pharmaceutical development expertise to academic-led research. They coordinated one smaller MSCA fellowship project (MS4Drug), suggesting they can lead focused research but prefer contributing to larger collaborative efforts. With 30 unique partners across 13 countries, they are well-networked and comfortable operating in diverse European consortia.

Chiesi has built a broad European network of 30 consortium partners spanning 13 countries, indicating they are well-connected across the EU research landscape. Their partnerships likely span academic hospitals, universities, and research institutes given the clinical and translational nature of their projects.

What sets them apart

Chiesi stands out as a large pharmaceutical company that actively engages in EU collaborative research — many pharma companies of their size avoid the complexity of H2020 consortia. Their dual expertise in neonatal medicine and neurodegenerative disease gives them a distinctive profile among industry partners. For consortium builders, Chiesi offers something rare: a pharma company with genuine clinical trial infrastructure and regulatory pathway knowledge willing to participate in pre-competitive research.

Highlights from their portfolio

• PREMSTEM
  Their largest H2020 investment (EUR 908,000), addressing stem cell therapies for premature infant brain injury — a high-impact translational research area.
• FAIR-PARK-II
  A multicentric clinical trial testing iron chelation as a disease-modifying strategy for Parkinson's, representing pharma-grade clinical research within an EU consortium.
• MS4Drug
  Their only coordinator role, a focused MSCA fellowship on mass spectrometry drug discovery — signals investment in building internal analytical capabilities.